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Abstract
Background: The elderly are frequently exposed to drug related problems causing hospitalizations and increased
costs of care. Information about Romanian prescribing practices among the elderly and potential medication
associated- risks is lacking. The objective of this study was to identify and compare the most frequent potentially
inappropriate medications (PIM) recommended to ambulatory and institutionalized Romanian elderly, through an
observational retrospective design.
Methods: All reimbursed medications prescribed to a sample of ambulatory elderly accessing two community
pharmacies and all medications recommended to a group of institutionalized elderly (urban facilities, Romania,
same month) were analyzed. The STOPP/START criteria and the PRISCUS list were used for PIM identification and for
classification as misprescribed, underprescribed or overprescribed -subtypes.
Results: The analysis involved 345 prescriptions recommended to ambulatory elderly and 91 medical files available
for the institutionalized patients. The ambulatory elderly had a mean age of 74.8 years old and were daily exposed
to a median number of 3 prescribed medications. The institutionalized elderly were older (mean age 80.77)
received 8 medications daily and 69 % of them were functionally dependent. Cardiovascular and neuropsychiatric
indications were the most frequent: 64.34 % and 18.55 % of the ambulatory prescriptions, 93.40 % and 41.75 % of
the institutionalized patients’ medical files. 159 PIM were identified on 34.49 % of the ambulatory prescriptions. 82.
41 % of the institutionalized patients’ medical files contained 140 PIM. The potential underprescribing of
cardiovascular therapies was the most frequent PIM category on the ambulatory prescriptions (55.34 % of all PIM),
while for the institutionalized patients’ medical files, the misprescribed and overprescribed PIM were those
predominantly represented (62.14 % and 27.14 % of all PIM). In both subgroups of data, NSAIDs (56.66 % of
ambulatory prescriptions and 35.63 % of institutionalized patients’ data) and benzodiazepines (26.66 % of
ambulatory prescriptions and 24.13 % of institutionalized patient’s data) were predominantly misprescribed.
Anticholinergics were rarely used (0.62 % of total PIM from ambulatory prescriptions, 2.14 % of total PIM from
institutionalized patients’ data).
Conclusions: The PIM identified in both elderly groups suggested potential risks for the occurrence of adverse
events specific to the elderly population. Larger studies, both observational and interventional, are needed to
ensure a safer therapeutic approach.
Keywords: Inappropriate prescribing, Drug -related problems, Ambulatory elderly, Institutionalized elderly, STOPP/
START criteria, PRISCUS list
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Background
Age-related changes influence the pharmacokinetic
pathways and the pharmacodynamic response of therap-
ies delivered to the elderly population, increasing the
risk for drug-related problems (DRP) which favor costly
and frequent hospitalizations, and augmenting the mor-
tality risk, irrespective of the environment of care [1–4].
The variability of the individual degree of functional
independence is another significant aspect influencing
therapeutic decisions that need to ensure functional
independence and prolong social insertion [5].
The potentially inappropriate medications (PIM) and
the corresponding phenomenon of potentially inappro-
priate prescribing (PIP) refer to the use of medications
identified through various studies as factors that expose
the elderly patient to safety or efficacy DRP. The litera-
ture suggests three subtypes for PIM: misprescribed PIM
involving medications with an increased risk for side ef-
fects or drug-interactions in the elderly, underprescribed
PIM relating to the absence of medications proved to be
effective for preventive or curative indications in the eld-
erly, and overprescribed PIM relating to the use of ther-
apies lacking therapeutic benefit [6, 7].
Such PIM can be identified in an individual thera-
peutic plan, using published explicit criteria consisting
of lists of medications to avoid, to use cautiously or to
actively recommend to the elderly. Several such vali-
dated instruments are available in the literature, having
different structures and medications: the Beers criteria
(USA), the STOPP/START (Screening Tool of Older
Persons’ Prescriptions/Screening Tool to Alert doctors
to Right, i.e. appropriate, indicated Treatment) criteria
(Ireland), the PRISCUS (Latin for “old and venerable”)
list (Germany) etc [8–10]. The potential warning func-
tion of such instruments was confirmed through various
investigations that intended to substantiate a relation-
ship between PIM use and negative outcomes in the eld-
erly. For example, the use of medications included in the
Beers 2012 and STOPP criteria was associated with ad-
mittance to the emergency department for 30.3 % of the
nursing home residents, followed by Grace et al. in a
retrospective cohort study, while Matanović et al. found
that 54 % of hospitalizations registered for 454 consecu-
tive ambulatory patients were associated with the use of
non-COX-selective NSAIDs, short- and intermediate-
acting benzodiazepines, and amiodarone, identified using
Beers criteria [11, 12]. Frankenthal et al. successfully
used STOPP/START as an instrument to influence mis-
prescribing in a chronic care geriatric facility. Therefore,
there was a reduction in the number of prescribed medi-
cations, therapy – associated costs and in the average
number of falls [13]. Furthermore, some of these instru-
ments were also used as quality measures in several
insurance programs, confirming their applicability in
large population groups [8]. However, various studies
showed that PIM identification with these instruments
depends on local availability of the included medications
and on local patterns of geriatric practice [14, 15].
Therefore, the simultaneous use of several such instru-
ments was suggested as a more efficient method for PIM
detection in elderly populations different from those
used as validation group for the original criteria [16].
The local population follows the aging trend identified
at an international level while the hospitalization rate
among the Romanian elderly has an annual increase of
17.82 % [17]. Romanian elderly generally have access to
prescribed medications, nonprescription medication and
to various natural products. The prescribed medications
can be partially or totally reimbursed by the national sys-
tem of heath care insurance and the community phar-
macies keep an electronic and printed record of the
reimbursed dispensed medications. The nonprescription
medications and natural products are neither reim-
bursed nor recorded. Professional activities such as
medication review of the elderly pharmacotherapy are
not mandatory and are usually conducted in an aca-
demic or research- related context. Detailed information
about the quality of medications used by the Romanian
elderly is lacking, but it is needed as it could suggest po-
tential directions for safety and efficacy optimization.
Therefore, the objective of this study was to identify the
PIM recommended for two subgroups of Romanian eld-
erly patients, ambulatory and institutionalized, using the
STOPP/START criteria and the PRISCUS list.
Methods
In this descriptive observational study, two collections of
data were analyzed: all reimbursed medications prescribed
to a sample of ambulatory elderly accessing two commu-
nity pharmacies and, respectively, all medications recom-
mended to a group of institutionalized elderly (urban
facilities, Romania). All patients were over 65 years old at
the time of the data collection and both data sets covered
the same 30-day interval (March 2013).
A prescription could contain one to several medica-
tions indicated for various conditions.
The pharmacies were selected by convenience as they
were considered to be representative for the majority of
local community pharmacies in terms of accessibility to
the elderly population and orientation towards patient's
care (one had an independent- pharmacist owner and
the other was included in a national chain of community
pharmacies). Both offered services and medications to
different population groups. For the ambulatory elderly,
the analyzed data excluded details involving the use of
nonprescription medications and natural products, as
their use was not registered in the available data collec-
tion. For the institutionalized elderly, the analysis
Primejdie et al. BMC Pharmacology and Toxicology  (2016) 17:38 Page 2 of 10
included all recommended medications (irrespective of
their reimbursement status), following the indications of
the primary-care physician who attended the facility.
The medical files of the institutionalized elderly had
variable levels of information related to medical history
and laboratory investigations.
The analysis used three sets of PIM identification
criteria: STOPP/START, the 2008 version (covering in-
stances of misprescribing, overprescribing and underpre-
scribing) and the PRISCUS list (misprescribing and
overprescribing) [9, 10]. These sets of criteria are differ-
ent in terms of need for patient's medical and medica-
tions history: the use of the STOPP/START tool
frequently requires access to patients’ clinical information,
while the PRISCUS list can be applied without such detail.
The availability of the medications or drug classes men-
tioned in these evaluation criteria was considered as ad-
equate for the descriptive purpose of the study: 63 (94 %)
of the 65 medications or drug classes included in the
STOPP criteria, 22 of the 22 (100 %) medications or drug
classes mentioned in the START criteria, 45 of the 83
(54 %) medications or drug classes included in the
PRISCUS list.
The study had a retrospective and observational char-
acter and formal consent was not required. The data
analysis ensured patient’s confidentiality. The project re-
ceived the approval of the local ethics committee. Two
clinical pharmacists collected and analyzed the
Table 1 Patients’ characteristics
Patients
Ambulatory elderly accessing 2 community pharmacies Institutionalized elderly in one nursing home facility
Collection of data
Prescriptions of reimbursed medications Medical files with all recommended medications
Items of data included in
each collection
345 prescriptions 91 medical files
mean age (±SD) (years old) 74.8 (±6.24) 80.77 (±6.82)
range of individual age 65-92 years old 65-98 years old
women (% of the elderly patients,
in the each population group)
211 (61.16 %) 53 (58.24 %)
age groups
65-75 years old 193 (55.94 %) 21 (23.08 %)
76-85 years old 129 (37.39 %) 48 (52.75 %)
>85 years old 23 (6.66 %) 22 (24.17 %)
number of medications in each
collection of data
1111 752
median number of medications/
item of data
3 8
Diagnoses mentioned in each collection of data
total number of diagnoses 748 399
median number of diagnoses/item
of data
2 4
Frequency of types of diagnoses in each collection of data
Type of diagnosis number of prescriptions with the respective type of
diagnosis (% of the total number of prescriptions)
number of medical files with the respective type of
diagnosis (% of the total number of medical files)
cardiovascular 222 (64.34 %) 85 (93.40 %)
neuropsychiatric 64 (18.55 %) 38 (41.75 %)
rheumatologic 61 (17.68 %) 33 (36.26 %)
diabetes 58 (16.81 %) 14 (15.38 %)
gastrointestinal 26 (7.53 %) 12 (13.18 %)
respiratory 28 (8.11 %) 5 (5.49 %)
urologic 20 (5.79 %) 10 (10.98 %)
ophthalmologic 16 (4.63 %) 10 (10.98 %)
other 25 (7.24 %) 24 (26.37 %)
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information available in the two data sets, using specific
data collection forms. Descriptive statistics were used
(Microsoft® Office Excel 2007, Microsoft Corporation).
Results
The two pharmacies delivered 345 prescriptions to the
elderly ambulatory patients (34.36 % from a total of
1,004 reimbursed prescriptions delivered to all the pa-
tients accessing the pharmacies), covering both chronic
and acute indications (Table 1). The proportion of pre-
scriptions delivered to the elderly patients differed
between the two pharmacies. For one pharmacy, the pre-
scriptions delivered to the elderly ambulatory patients
covered 48.64 % of all reimbursed prescriptions (180 of
370 prescriptions), while for the other pharmacy, they
represented 26.01 % of all reimbursed prescriptions (165
of 634 prescriptions). Among the 91 institutionalized
elderly 58 (64 %) of them had dementia, 63 (69 %) were
functionally dependent (severe dementia or bedridden),
while 10 elderly (14 %) had severe renal disease (creatin-
ine clearance ≤ 30 ml/min, estimated with the Cockroft
Gault equation).
Considering the three sets of explicit criteria, 119 pre-
scriptions (34.49 %) presented 159 PIM, with an average
(±SD) of 0.46 (±0.73) PIM/ambulatory elderly prescrip-
tion and a maximum of 4 PIM/ambulatory elderly pre-
scription. 75 medical files (82.41 %) contained 140 PIM,
with an average (±SD) of 1.53 (±1.12) PIM/institutional-
ized elderly medical file and a maximum of 6 PIM/insti-
tutionalized elderly medical file. The underprescribed
PIM were most frequent among the ambulatory elderly,
while the misprescribed subtypes were frequent among
those institutionalized (Tables 2 and 3).
For osteoarthritic pain, ambulatory elderly used vari-
ous non-selective NSAIDs and coxibs, while the institu-
tionalized elderly were exposed to diclofenac and
ketoprofen administered intramuscularly. NSAIDs were
co-prescribed with cardiovascular medications on 29
(85.30 % of 34) prescriptions and on 25 (80.64 % of 31)
medical files presenting NSAIDs. 26 (76.5 % of 34)
prescriptions and 27 (87.1 % of 31) medical files had
NSAIDs recommended for more than 10 days/month,
without concurrent therapy with a proton pump inhibi-
tor. 24 (70.58 %) of NSAIDs prescriptions covered ≤ 20/
30 days of analgesic therapy, in the absence of supple-
mental analgesic approaches. 21 (23.07 %) of the institu-
tionalized elderly presented a diagnosis associated with a
persistent pain syndrome, but lacked analgesic therapy.
Acetaminophen was not recommended in the nursing
home.
Typical and atypical antipsychotics were regularly used
in the nursing home. 17 elderly with dementia (29.31 %
of all 58 having a dementia diagnosis) received such
therapy. Short to long-acting benzodiazepines were rec-
ommended for daily use in both environments of care.
Vasodilators and circulation-promoting agents (pentoxi-
fylline, Ginkgo biloba standardized extract, nicergoline,
vinpocetine) were used by 26 (44.82 %) of the 58 institu-
tionalized elderly with dementia and by 17 (26.98 %) of
those 63 functionally dependent.
The items from the STOPP/START criteria requiring
access to clinical information (medical history, medica-
tion history, degree of severity, intolerances or contra-
indications etc.) were not applicable for the prescription
analysis or for the majority of the included medical files,
as the relevant clinical details were not available. For the
ambulatory elderly, the STOPP/START criteria referring
to the use of aspirin as an antiplatelet agent, of dipyrid-
amole, loperamide or of calcium and vitamin D were not
applied, as they refer to over-the-counter medications,
not registered in the available database. Several medica-
tions from the PRISCUS list, although locally available,
were not prescribed: ergotamine and its derivatives,
muscle relaxants, baclofen, tetrazepam, clonidine, alpha-
blockers, methyldopa, fluoxetine, ticlopidine, prasugrel,
nitrofurantoin, sotalol, pethidine, phenobarbital.
Discussion
This study identified several categories of PIM pre-
scribed to two samples of elderly with different
Table 2 Types of potentially inappropriate medications (PIM)
Analyzed sample of medications
1111 medications prescribed to the ambulatory
elderly
752 medications recommended to the
institutionalized elderly
Total number of PIM in each sample of medications
159 140
Subtype – PIM
Misprescribed – PIM (% of total number of
PIM)
60 (37.73 %) 87 (62.14 %)
Underprescribed - PIM (% of total number
of PIM)
88 (55.34 %) 15 (10.71 %)
Overprescribed - PIM (% of total number of
PIM)
11 (6.92 %) 38 (27.14 %)
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Table 3 Potentially inappropriate medications (PIM) identified in the ambulatory and institutionalized elderly pharmacotherapy
Medications prescribed on 345 reimbursed
prescriptions delivered to ambulatory elderly
Medications recommended
on 91 medical files of the
institutionalized elderly
Subtype – PIM Reference criteriaa: reason to avoid no. of
examples of
subtype- PIM
















Misprescribed – PIM 60 87
NSAIDs as chronic analgesics in osteoarthritis
PRISCUS list –analgesics, anti-inflammatory drugs:
– very high risk of gastrointestinal hemorrhage,
ulceration, or perforation, which may be fatal
– indometacin: central nervous disturbances
– phenylbutazone: blood dyscrasia
– etoricoxib: cardiovascular contraindications
STOPP tool - Musculoskeletal system
− NSAID with heart failure
− Warfarin and NSAID together
34 56.66 21.38 31 35.63 22.14
benzodiazepines
PRISCUS - sedatives, hypnotic agents:
– risk of falling (muscle-relaxing effect) with risk of hip fracture
– prolonged reaction times
– psychiatric reactions (can also be paradoxical,
e.g., agitation, irritability, hallucinations, psychosis)
– cognitive impairment
– depression
16 26.66 10.06 21 24.13 15.00
antipsychotics
PRISCUS- neuroleptic drugs:





– risk of falling
– increased mortality in demented patients
3 5.00 1.88 18 20.68 12.85
digoxin for heart failure > 0.125 mg/day
PRISCUS list- Antiarrhythmic drugs:
– elevated glycoside sensitivity (women >men)
– risk of intoxication
STOPP tool - Cardiovascular system:
- digoxin at a long-term dose > 125 μg/day
with impaired renal function
4 6.66 2.51 13 14.94 9.28
anticholinergic drugs (trihexyphenidyl, doxepine)
PRISCUS list- Anticholinergic drugs:
– anticholinergic side effects (e.g., constipation, dry mouth)
– impaired cognitive performance
– ECG changes (prolonged QT)
PRISCUS list - Tricyclic antidepressants:
– peripheral anticholinergic side effects (e.g., constipation,
dry mouth, orthostatic hypotension, cardiac arrhythmia)
– central anticholinergic side effects (drowsiness, inner unrest,
confusion, other types of delirium)
– cognitive deficit
– increased risk of falling
STOPP tool - Central nervous system and psychotropic drugs:
– anticholinergics to treat extrapyramidal side effects of
neuroleptic medications (risk of anticholinergic toxicity)
1 1.66 0.62 3 3.44 2.14
Duplicate drug classes (two concurrent NSAIDs, ACE inhibitors, ARBs)
STOPP tool - Duplicate drug classes:
- any duplicate drug class prescription.
2 3.33 1.25 1 1.14 0.71
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functional capacities and medical complexities, through
the use of specific tools validated to this end: the
STOPP/START criteria and the PRISCUS list. We found
that 34.49 % of the prescriptions delivered to the ambu-
latory elderly and 82.41 % of the institutionalized
patients were exposed to PIM. We decided to analyze
these two elderly populations as they represent an
appropriate environment for a more active pharmacist’s
involvement in the complex process of geriatric care
optimization. Although such pharmaceutical care activ-
ities are encouraged, their local necessity and benefit, in
terms of safety and efficacy of elderly care, are to be
demonstrated. Therefore, although our analysis covered
a short period of time, it represents a first necessary step
in a pilot project aimed at creating a screening instru-
ment for PIM, specific to local prescribing practices and
adapted for use by the local community pharmacists.
Considering their potential clinical significance, our re-
sults could also initiate a pharmacist- prescriber dialogue
aiming for a more geriatric- oriented process of care, in
terms of both efficacy and safety. Furthermore, both the
frequency and nature of the identified PIM suggest the
need for further studies evaluating their likely impact on
hospitalization rate or care- associated costs.
This is also the first study using the STOPP/START
criteria and the PRISCUS list in conjunction, as explicit
criteria for PIM identification in two samples of elderly
patients cared for in two different environments. As
Table 3 Potentially inappropriate medications (PIM) identified in the ambulatory and institutionalized elderly pharmacotherapy
(Continued)
Underprescribed - PIM 88 15
underprescribing of statins in coronary vascular disease
START tool - Cardiovascular system:
- Statin therapy with a documented history of coronary,
cerebral or peripheral vascular disease, where the
patient’s functional status remains independent for
activities of daily living and life expectancy is greater
than 5 years
46 52.27 28.93 1 6.66 0.71
underprescribing of β-blocker with chronic stable angina
START tool - Cardiovascular system:
- Beta-blocker with chronic stable angina.
29 32.95 18.23 0 0 0
underprescribing of acenocoumarolb in the presence
of chronic atrial fibrillation
START tool - Cardiovascular system:
- Warfarin in the presence of chronic atrial fibrillation.
8 9.09 5.03 0 0 0
underprescribing of antihypertensive therapy where systolic
blood pressure consistently > 160 mmHg
START tool - Cardiovascular system:
- Antihypertensive therapy where systolic
blood pressure consistently > 160 mmHg.
not applicablec 7 46.66 5.00
underprescribing of ACE inhibitors with chronic heart failure
START tool - Cardiovascular system:
- ACE inhibitor with
chronic heart failure
3 3.40 1.88 2 13.33 1.42
underprescribing of statins in diabetes mellitus
START tool - Endocrine system:
- Statin therapy in diabetes mellitus if coexisting
major cardiovascular risk factors present
1 1.13 0.62 4 26.66 2.85
underprescribing of ACE inhibitors following acute
myocardial infarction
START tool - Cardiovascular system:
- ACE inhibitor following acute myocardial infarction
1 1.13 0.62 1 6.66 0.71
Overprescribed - PIM 11 38
overprescribing of anti-dementia drugs, vasodilators,
circulation-promoting agentsd
PRISCUS - anti-dementia drugs, vasodilators,
circulation-promoting agents
– no proof of efficacy, unfavorable risk/benefit profile
11 100.00 6.91 38 100.00 27.14
aref. [9, 10]
bacenocoumarol is the local available antivitamin K (warfarin in the START criteria)
cthe information available on the prescription did not include the blood pressure values
dPentoxifylline, Ginkgo biloba standardized extract, nicergoline, vinpocetine
ARB Angiotensin II Receptor Blocker, ACE Angiotensin Converting Enzyme, NSAIDs nonsteroidal anti-inflammatory drugs
Percentages are presented as unrounded numbers
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suggested by previous similar research, the methodology
used in this observational study tried to overcome the
inherent limitations of explicit criteria, through the sim-
ultaneous use of three such European instruments [18].
Although several criteria referring to misprescribing in-
stances, included in the STOPP tool overlapped with
those of the PRISCUS list, their simultaneous use was
considered as useful for the identification of the particu-
lar medication use patterns among the two subgroups.
As the clinical information necessary for the application
of these two sets of criteria is different (the STOPP cri-
teria frequently refers to the patients’ medical or medica-
tion background, while the PRISCUS list does not), this
aspect was considered appropriate, considering the fact
that the prescriptions delivered to the ambulatory pa-
tients lacked the clinical detail, while this was present on
the medical files of the institutionalized patients. There-
fore, the limited access to the patient’s medical history
or to information about the use of nonprescription med-
ications proved to be an important although predictable
obstacle in the use of all STOPP/START criteria refer-
ring to medications locally available. For example the
STOPP criteria referring to the use of aspirin as an anti-
platelet agent or the START criteria referring to the
underuse of effective antihypertensive agents could not
be used in the analysis of the ambulatory elderly therapy.
This difference in applicability can partially justify the
difference in terms of PIM frequency among the 2 sets
of data. Moreover, this observation suggests caution in
the interpretation of the results as the STOPP/START
authors proved that misprescribed PIM are likely to be
overestimated using STOPP and underprescribed PIM
are likely to be underestimated using START, when the
community pharmacist’s analysis lacked patients’ clinical
details [19].
This higher exposure to PIM of the institutionalized
elderly is a result confirmed in similar comparative stud-
ies that found institutionalization as a risk factor for PIP.
Haasum et al. found that 30 % of the institutionalized
and 12 % of the home-dwelling elderly were exposed to
anticholinergic drugs, long-acting benzodiazepines, and
concurrent use of 3 or more psychotropics [20]. Shah et
al. confirmed this gap in PIM burden among the com-
munity and nursing home residents and also found a
similar and significant difference in the number of daily
medications administered to both populations: 4.9 in the
community and 8.4 in care homes (3.22 and 8.26 daily
medications, respectively, in our study), suggesting the
increased risk for PIP as a consequence of the institu-
tionalized elderly exposure to polypharmacy [21].
Polypharmacy is a prevalent geriatric phenomenon, cor-
related with increased care-related costs and greater
mortality especially among those cognitively impaired
[22]. The risk for polypharmacy is increased when
medications with debatable benefit are being used, espe-
cially among those with limited life expectancy, for
whom 40 to 50 % of the recommended medications can
be considered as useless or overused [23]. From this
point of view, the administration of vasodilators and
various circulation-promoting agents (pentoxifylline,
Ginkgo biloba standardised extract, nicergoline, vinpoce-
tine) recommended as antidementia therapy to both popu-
lations, could be considered as potentially overprescribed.
They represented 6.91 % of all ambulatory PIM and
27.14 % of all institutionalized elderly PIM, although the
evidence of their benefit is reduced and concerns have been
expressed regarding the potential for increased
hemorrhagic risk, as stated by the PRISCUS criteria [10,
24].
The most frequent PIM categories identified were also
different between the two environments of care: the
underprescribed (55.34 %) and misprescribed (37.73 %)
subtypes prevailed for the ambulatory elderly, while the
misprescribed (62.14 %) and overprescribed (27.14 %)
subtypes were more frequent in the institutionalized
sample. Similarly to our study, Silva et al. used STOPP/
START on a sample of institutionalized elderly and
found a higher proportion of misprescribed PIM com-
pared to the underprescribed cases: 76.82 % were
STOPP criteria and 23.18 % were START criteria in their
study [25]. The most prevalent examples were different
nevertheless, as in our study the institutionalized elderly
were mostly exposed to the high use of NSAIDs and to
the underuse of antihypertensive therapy.
The misprescribed and underprescribed PIM identi-
fied through the use of STOPP/START criteria are
comparable to others available in the literature. For
example, a systematic review that included 12 pro-
spective or retrospective observational studies and
one randomized clinical trial, which applied full or
modified STOPP/START on health records, found a
variable frequency of PIM use, influenced by study
design, ranging from 21.4 % to 79 %. Some of the
identified PIM are similar to those of the present
study: recommendations of long-acting benzodiazepines,
benzodiazepines with long-acting metabolites, neurolep-
tics or underuse of statins in patients with documented
history of coronary, cerebral or peripheral vascular disease
[26]. Several studies that applied the PRISUS list of criteria
were also identified. For example, one large-scale German
analysis found that 25 % of the elderly received at least
one PIM, with amitriptyline, acetyldigoxin, tetrazepam
and oxazepam as the most frequent misprescribed PIM
[27]. Reich et al. applied the PRISCUS list and the Beers’
2012 criteria on health care claims data of four health
insurers for managed care elderly in Switzerland, and
found a 22.5 % estimated prevalence of PIM. PIM use
was significantly associated with increasing number of
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chronic diseases or hospitalizations and again with
polypharmacy [28].
The main PIM subtypes identified among the am-
bulatory elderly were the underprescribing of statins
or β-blockers in coronary heart disease (47.16 % of all
PIM), recommended to reduce mortality and morbid-
ity even in the elderly population. The clinical
relevance of these recommendations suggesting
prophylactic approaches with a relative delayed bene-
fit is however limited in the case of the frail elderly,
frequently institutionalized, who could have different
care needs [29]. Although the data available for the
ambulatory elderly did not allow for the assessment
of their degree of functionality, these results are simi-
lar to others showing a reduced use of prophylactic
cardiovascular therapies or a trend of progressive re-
duction of use of cardiovascular therapies in nursing
homes, especially for patients over 80–85 years old
[21, 30]. Moreover, we found that 7.69 % of the insti-
tutionalized elderly could have benefited from the in-
tensification of the antihypertensive regimen, as indicated
by the START criteria, although this approach requires
individualization in a population subgroup with a theoret-
ically reduced life-expectancy [31].
The most frequent subtype of misprescribed PIM,
identified in both environments of care, was the use of
NSAIDs as analgesics in osteoarthritis, representing
56.66 % of total misprescribed -PIM in the ambulatory
sample and 35.63 % of total misprescribed -PIM on the
medical files, frequently associated with cardiovascular
therapies or lacking gastro- protective agents. The
amount of clinical information available for the ambula-
tory elderly could not allow for the assessment of the
duration of use or for the presence of renal dysfunction
in these patients, but the cardiovascular, gastrointestinal,
central nervous system or renal risks remain a serious
concern for potential safety- DRP [32]. The results are
comparable to those obtained in similar studies that
identified a reduced gastrointestinal protection among
the elderly exposed to NSAIDs use [33]. The fact that
for the institutionalized and generally frailer population,
the potential misuse of NSAIDs represented the most
frequent instance of PIP suggested the need for the
reevaluation of the implemented pain management strat-
egies. Furthermore, the NSAIDs use among other nurs-
ing home populations, described in the literature, was
significantly lower (1.2 % or 3.8 %), as acetaminophen or
opioids represented the preferred analgesic approach
[21, 34]. The majority of products containing acetamino-
phen are available locally without a prescription and
therefore they were not reimbursed, so their use could
not be monitored in our ambulatory sample. Acetamino-
phen was not recommended to the institutionalized eld-
erly so questions arise concerning its real use as an
analgesic. Furthermore, it is difficult to ascertain the an-
algesic therapies used by the 71 % of the ambulatory eld-
erly with persistent pain, having less than a 30 days
duration recommendation for NSAIDs. Additionally, less
than 8 % of the elderly from every sample used weak
opioids and adjuvants. Although the underuse of pain
medications is not a criterion in the START tool used in
this analysis, our findings are in agreement with those
identified through a European multicenter analysis,
which identified a 48.4 % prevalence of analgesic under-
use among institutionalized elderly [35]. Despite the fact
that the recently published STOPP/START criteria ver-
sions 2 were not available at the time of our data collec-
tion, this recent version considers as a START criterion,
the use of high-potency opioids in moderate-severe pain
and underscores the need for efficient pain management
in the elderly [36].
Long-acting benzodiazepines, zolpidem and zopiclone
were identified on 4.64 % of the ambulatory elderly pre-
scriptions and on 23.08 % of the institutionalized elderly
medical files, for the management of both anxiety or in-
somnia. These molecules can have negative effects on
the cognitive and motor functions, favoring falls and
fractures with unproved benefits from long-term use
[37, 38]. Bourgeois et al. and de Souto Barreto et al.
identified a higher benzodiazepine use (50 % or 53.4 %)
among the institutionalized Belgian and French elderly,
correlated with the presence of pain syndromes and
polypharmacy, but the administration of long half-life
molecules or of unadjusted dosages represented poten-
tial DRP common to our subgroup [39, 40]. Among the
ambulatory 70–89 years old Norwegian population,
Neutel et al. found a higher benzodiazepine use that the
one identified in our subgroup, with a 12.3 % prevalence
of inappropriate use of benzodiazepines as hypnotics or
anxiolytics [41]. Almost 20 % of the institutionalized
elderly received antipsychotics, with haloperidol as the
most frequently prescribed, while their use was infre-
quent in the ambulatory sample. Our findings are com-
parable to other similar investigations, as antipsychotic
prescribing in Belgian nursing homes varied from 17.6 %
to 32.9 % depending on study methodology [42, 43].
Antipsychotic use increases among the demented insti-
tutionalized elderly, having as potential indication the
control of their neuropsychiatric symptoms or delirium
episodes. Their use was associated with extrapyramidal,
cardiovascular and cerebrovascular events and with an
increased risk of mortality derived especially from the
use of typical molecules [10, 44]. Both STOPP and PRIS-
CUS criteria enlist the use of anticholinergic medica-
tions as unsafe in the elderly, but our data showed a
limited prescription of these molecules (0.62 % of total
PIM in the ambulatory elderly and 2.14 % of those insti-
tutionalized) by comparison with similar European or
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North American studies, that identified a 20.7 % and
73.62 % exposure in the institutionalized patients [45,
46]. These findings can be explained by a more reduced
availability on the market of the anticholinergic medica-
tions presented in the criteria and also by different pat-
terns of medication use in the elderly.
The limits of this study are a consequence of its retro-
spective nature and of the reduced scale of the data sets
used for the analysis, which limit the generalization of
these results. Medical history (including cognitive and
functionality status) for the ambulatory patients was not
available, nor was the information concerning the use of
nonprescription medications or natural products. The
available clinical detail concerning both collections of
data was too limited to allow for the enquiry of several
items included in the STOPP/START criteria, which re-
quire access to clinical information. The patient’s adher-
ence to the recommended therapies was not known. For
both environments of care, the analysis referred to the
prescribed medications and not to those actually taken
by the elderly patients.
Conclusions
Our study identified a potentially inappropriate use of
NSAIDs as chronic analgesics in osteoarthritis both in
ambulatory and institutionalized elderly, a reduced use
of prophylactic cardiovascular therapies among the am-
bulatory elderly and a high overprescribing potential of
vasodilators or circulation-promoting agents in the insti-
tutionalized sample. The necessity for a more consistent
consideration of the risks implied by the aging process
became evident. The results of our study encourage their
confirmation through more complex investigations or
more detailed analysis of the potential impact of the
identified PIM on the rate of hospitalization or on care-
related costs and could justify future interventional
studies intended to optimize the elderly patient's
pharmacotherapy.
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